Ampio Pharmaceuticals Announces Positive Results on Ampion Trial for Relief of Nasal Inflammation

Ampio Pharmaceuticals, Inc. AMPE today announced that an IRB approved, randomized, vehicle-controlled, double-blinded study conducted at Centers for Allergy and Asthma in Denver, Colorado indicates that Ampion™ provides safe and effective anti-inflammatory relief when administered intranasally to patients with nasal inflammation. According to Dr. David Bar-Or, Chief Science Officer of Ampio, "Twenty patients were randomized to receive either intranasal Ampion™, or saline, twice a day during a 10 day double-blind period which followed a one week washout period. The subjects reported reflective total nasal symptom scores (rTNSS) as well as instantaneous total nasal symptom scores (iTNSS) every 12 hours. A trend of improvements in rTNSS was observed in the intranasal Ampion™ group over the saline group. When stratifying patients by baseline severity of symptoms, Ampion™ was found to have greater efficacy in the moderately symptomatic patients (mean baseline rTNSS less than 7.5) and despite the limited number of patients in this stratum the difference between saline and Ampion™ reached statistical significance (p=0.045).